Zoetis Inc. $ZTS Stock Purchased by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. boosted its position in Zoetis Inc. (NYSE:ZTS) by 48.0% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 172,115 shares of the company’s stock after purchasing an additional 55,840 shares during the period. Oppenheimer & Co. Inc.’s holdings in Zoetis were worth $12,019,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. Flossbach Von Storch SE bought a new stake in shares of Zoetis in the 2nd quarter valued at about $302,601,000. BlackRock Inc. lifted its stake in shares of Zoetis by 10.8% in the second quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock worth $2,833,453,000 after acquiring an additional 3,845,869 shares during the period. Ruane Cunniff & Goldfarb L.P. acquired a new position in shares of Zoetis in the first quarter worth approximately $286,660,000. Southpoint Capital Advisors LP lifted its position in shares of Zoetis by 340.0% in the 1st quarter. Southpoint Capital Advisors LP now owns 2,200,000 shares of the company’s stock worth $260,062,000 after purchasing an additional 1,700,000 shares during the period. Finally, Carmignac Gestion bought a new stake in Zoetis during the second quarter valued at $113,230,000. 92.80% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. TD Cowen cut their price target on Zoetis from $104.00 to $94.00 and set a “buy” rating on the stock in a report on Tuesday, August 25th. JPMorgan Chase & Co. decreased their price objective on Zoetis from $130.00 to $115.00 and set an “overweight” rating for the company in a report on Friday, August 7th. BNP Paribas Exane lowered their target price on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating for the company in a report on Tuesday, August 11th. Barclays decreased their price target on Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 1st. Finally, Zacks Research lowered shares of Zoetis from a “hold” rating to a “strong sell” rating in a research report on Monday, August 10th. Seven investment analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $98.40.

Zoetis Trading Down 3.4%

Shares of NYSE:ZTS opened at $78.25 on Wednesday. The firm has a fifty day moving average of $74.84 and a 200 day moving average of $94.35. Zoetis Inc. has a 52-week low of $68.77 and a 52-week high of $147.46.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. The business had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. Zoetis’s revenue for the quarter was down .2% on a year-over-year basis. During the same period last year, the company posted $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, equities analysts anticipate that Zoetis Inc. will post 6.15 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Stockholders of record on Friday, October 30th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Friday, October 30th.

About Zoetis

Zoetis Inc is a global animal health company that develops, manufactures and markets medicines, vaccines, diagnostics, genetic products and related services for animals. Its offerings support the prevention, diagnosis and treatment of disease in both companion animals, including dogs, cats and horses, and livestock such as cattle, swine, poultry and fish.

The company’s product portfolio includes prescription medicines, parasiticides, vaccines, veterinary diagnostics and animal genetics.